Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Endometrial Cancer - Overview
Endometrial Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Endometrial Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endometrial Cancer - Companies Involved in Therapeutics Development
Endometrial Cancer - Drug Profiles
Endometrial Cancer - Dormant Projects
Endometrial Cancer - Discontinued Products
Endometrial Cancer - Product Development Milestones
Featured News & Press Releases
Sep 29, 2022: Imvax presents new data on persolized whole-tumor derived immunotherapeutic platform at 2022 Intertiol Cancer Immunotherapy Conference
Sep 13, 2022: Eisai presents new data on lenvatinib from its oncology portfolio and pipeline at ESMO Congress 2022
Aug 17, 2022: Mersa begins dosing in Phase I solid tumour therapy trial
Aug 03, 2022: ProfoundBio receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 inhibitor payload, and welcomes omi Hunder, M.D., as Chief Medical Officer
Jul 14, 2022: Theratechnologies provides update on the dose escalation portion of Fast Track desigted TH1902 first-in-human study in advanced resistant maligncies
Jul 12, 2022: Leap Therapeutics announces initiation of new DKN-01 clinical trials in gastric cancer, colorectal cancer and endometrial cancer
Jun 27, 2022: Harbour BioMed announces IND clearance for B7H4x4-1BB bispecific antibody by the U.S. Food and Drug Administration
Jun 03, 2022: Made-in-Singapore cancer drug ETC-159 advances in clinical trials
May 26, 2022: Karyopharm to present new Selinexor data at the 2022 American Society of Clinical Oncology Annual Meeting
May 11, 2022: Amber Specialty Pharmacy added to Eisai’s LENVIMA Network
May 05, 2022: Context Therapeutics announces poster presentation at the upcoming 2022 ASCO Annual Meeting
Apr 28, 2022: Clovis Oncology highlights Rubraca data to be presented at 2022 ASCO Annual Meeting
Apr 27, 2022: Karyopharm announces selinexor data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting
Apr 08, 2022: Sutro Biopharma presents nonclinical data for antibody-drug conjugate STRO-002 at the AACR Annual Meeting 2022
Apr 05, 2022: Nurix Therapeutics doses first patient in phase 1 clinical trial of DeTIL-0255, a drug-enhanced cell therapy for the treatment of patients with solid tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Endometrial Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Endometrial Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Endometrial Cancer - Dormant Projects, 2022
Endometrial Cancer - Discontinued Products, 2022
Endometrial Cancer - Discontinued Products, 2022 (Contd..1)